Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.

ABSTRACT:

Purpose

Ipilimumab, a monoclonal antibody inhibiting CLTA-4, is an established treatment in metastatic melanoma, either alone or in combination with nivolumab, and results in immune mediated adverse events, including endocrinopathy. Hypophysitis is one of the most common endocrine abnormalities. An early recognition of hypophysitis may prevent life threatening consequences of hypopituitarism; therefore, biomarkers to predict which patients will develop hypophysitis would have clinical utility. Recent studies suggested that a decline in TSH may serve as an early marker of IH. This study was aimed at assessing the utility of thyroid function tests in predicting development of hypophysitis.

Methods

A retrospective cohort study was performed for all patients (n = 308) treated wi

SUBMITTER: Siddiqui MS 

PROVIDER: S-EPMC7796881 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature